GlassScriptPhysician profile
Alysha Hinson
NPI 1093349078
$3,742.28
in general payments reported to CMS, 2019-2025
27 companies · $810 in 2025
The $810 reported for 2025 was more than what 94% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
See the full distribution for Women's Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $177 · 2022: $807 · 2023: $1,381 · 2024: $568 · 2025: $810.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,568 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,568.32 |
| Education | $189.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $791.57 | 2023-2025 | Veozah, Myrbetriq |
| Exeltis, USA INC. | $371.45 | 2021-2025 | Slynd, Solosec |
| Sumitomo Pharma America, INC. | $293.59 | 2023-2025 | Myfembree |
| Amgen INC. | $267.79 | 2022-2024 | Evenity, Prolia |
| Abbvie INC. | $261.07 | 2022-2025 | |
| Pfizer INC. | $227.04 | 2022-2025 | |
| Hologic Sales and Service, LLC | $198.34 | 2022-2024 | Novasure, Myosure Tissue Removal Device |
| Bayer Healthcare Pharmaceuticals INC. | $195.53 | 2021-2025 | |
| Evofem Biosciences, INC. | $186.71 | 2022-2025 | Phexxi, Solosec, Phexx |
| Shield Therapeutics INC | $179.46 | 2022-2025 | Accrufer |
| Sage Therapeutics, LLC | $154.87 | 2023-2025 | Zurzuvae |
| Mayne Pharma Commercial LLC | $95.54 | 2023-2025 | |
| Avion Pharmaceuticals | $80.95 | 2022-2023 | Balcoltra |
| Aspira Women'S Health INC | $59.51 | 2021 | |
| Millicent US INC | $56.77 | 2024-2025 | Intrarosa, Femring, Femlyv |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $53.89 | 2025 | Qelbree |
| Therapeuticsmd, INC. | $47.35 | 2021-2022 | |
| Seqirus USA INC | $33.45 | 2025 | Flucelvax, Fluad |
| Novo Nordisk INC | $31.95 | 2023-2024 | Wegovy |
| Organon LLC | $27.83 | 2022-2023 | Nexplanon |
| Welch Allyn | $24.97 | 2021 | |
| Scynexis, INC. | $20.01 | 2022 | |
| Myovant Sciences INC. | $19.36 | 2022 | |
| Boston Scientific Corporation | $18.91 | 2024 | Wavewriter Alpha Prime 16 |
| Smith+Nephew, INC. | $17.21 | 2025 | Pico |
| Medtronic, INC. | $14.22 | 2025 | Ligasure |
| Lupin INC. | $12.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alysha Hinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.